GetTopicDetailResponse(id=1b50e5503d2, topicName=突變性, introduction=突變性, content=null, image=null, comments=3, allHits=848, url=https://h5.medsci.cn/topic?id=75503, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=8798, tagList=[TagDto(tagId=8798, tagName=突變性)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1803515, encodeId=5c751803515be, content=<a href='/topic/show?id=1b50e5503d2' target=_blank style='color:#2F92EE;'>#突變性#</a>, objectTitle=Aprea的Eprenetapopt尚未達(dá)到治療TP53突變性骨髓增生異常綜合癥的主要終點(diǎn), objectType=article, longId=204980, objectId=817f204980c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=817f204980c0, replyNumber=0, likeNumber=101, createdTime=2021-05-28, rootId=0, userName=ms3892185887221420, userId=edaf2500125, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=817f204980c0, moduleTitle=Aprea的Eprenetapopt尚未達(dá)到治療TP53突變性骨髓增生異常綜合癥的主要終點(diǎn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=817f204980c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803514, encodeId=62631803514a4, content=<a href='/topic/show?id=1b50e5503d2' target=_blank style='color:#2F92EE;'>#突變性#</a>, objectTitle=Clin Cancer Res：抗瘧疾藥氯喹可增加GNAQ/11突變性黑色素瘤對(duì)MEK1/2抑制劑的敏感性！, objectType=article, longId=200796, objectId=d03f200e96fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d03f200e96fe, replyNumber=0, likeNumber=136, createdTime=2021-08-09, rootId=0, userName=ms3892185887221420, userId=edaf2500125, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d03f200e96fe, moduleTitle=Clin Cancer Res：抗瘧疾藥氯喹可增加GNAQ/11突變性黑色素瘤對(duì)MEK1/2抑制劑的敏感性！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d03f200e96fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803513, encodeId=3dd418035133e, content=<a href='/topic/show?id=1b50e5503d2' target=_blank style='color:#2F92EE;'>#突變性#</a>, objectTitle=BOA2013：奧拉帕尼維持治療可使BRCA突變性和鉑敏感的復(fù)發(fā)性漿液性卵巢癌患者獲益, objectType=article, longId=21190, objectId=fcdc211904f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcdc211904f, replyNumber=0, likeNumber=87, createdTime=2013-12-24, rootId=0, userName=ms3892185887221420, userId=edaf2500125, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcdc211904f, moduleTitle=BOA2013：奧拉帕尼維持治療可使BRCA突變性和鉑敏感的復(fù)發(fā)性漿液性卵巢癌患者獲益, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fcdc211904f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
